Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 5Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Plasmacytoma 2Paraproteinemias 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Plasma Cell 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Patient Preference 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1CD20-positive Hematological Malignancies 1Bile Duct Neoplasms 1Advanced Solid Tumors 1

Interventions

ridaforolimus 1Injections, Subcutaneous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Cancers × Injections, Subcutaneous × Clear all
NCT07260708 2026-04-21

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Recruiting
42 enrolled

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡